CombiGene
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | - | - | 8.2m | 2.4m | 2.6m |
| % growth | - | (100 %) | - | - | - | (71 %) | 8 % |
| EBITDA | - | - | (1.7m) | (2.7m) | 2.3m | (1.6m) | - |
| % EBITDA margin | - | - | - | - | 28 % | (65 %) | - |
| Profit | (<1m) | (1.3m) | (1.7m) | (2.9m) | 2.0m | (<1m) | - |
| % profit margin | (299 %) | (164350 %) | - | - | 25 % | (23 %) | - |
| EV / revenue | - | 5957.0x | - | - | 1.1x | 1.8x | - |
| EV / EBITDA | - | - | -3.6x | -2.7x | 3.8x | -2.8x | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€3.3m | Grant | ||
* | N/A | N/A | IPO |
* | N/A | Post IPO Equity | |
| Total Funding | €3.3m | ||
Recent News about CombiGene
EditCombiGene AB is a pioneering gene therapy company based in Lund, Sweden, and is recognized as the leading gene therapy firm in the Nordic region. The company focuses on developing innovative treatments for neurological and metabolic diseases. CombiGene's primary projects include CG01, aimed at treating epilepsy, and a new project targeting lipodystrophy, a rare metabolic disorder.
The company operates in the biotechnology and pharmaceutical market, serving patients, healthcare providers, and research institutions. CombiGene's business model revolves around research and development (R&D) of gene therapies, which involves identifying genetic solutions to treat specific diseases, conducting clinical trials, and eventually bringing these therapies to market. The company generates revenue through a combination of funding from research grants, partnerships with other pharmaceutical companies, and potential future sales of its gene therapy products.
One of CombiGene's flagship projects, CG01, has received significant funding from the European Horizon 2020 research and innovation program. This project focuses on developing a gene therapy treatment for epilepsy, a neurological disorder characterized by recurrent seizures. The funding from Horizon 2020 underscores the potential impact and innovation of CombiGene's work in this area.
In addition to CG01, CombiGene is also working on a project to address lipodystrophy, a condition that affects fat distribution in the body and can lead to severe metabolic complications. This project is still in the early stages but represents a significant expansion of CombiGene's therapeutic focus.
CombiGene's strategic location at Medicon Village, a renowned life sciences hub, provides it with access to cutting-edge research facilities and a collaborative environment with other biotech firms and academic institutions. This setting enhances CombiGene's ability to innovate and advance its gene therapy projects.
Keywords: Gene Therapy, Biotechnology, Epilepsy, Lipodystrophy, Neurological Diseases, Metabolic Disorders, Horizon 2020, Research and Development, Pharmaceutical, Nordic Region.